[HTML][HTML] Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity
RS Ranaweera, X Yang - Journal of Biological Chemistry, 2013 - ASBMB
The RING domain E3 ubiquitin ligase Mdm2 is the master regulator of the tumor suppressor
p53. It targets p53 for proteasomal degradation, restraining the potent activity of p53 and …
p53. It targets p53 for proteasomal degradation, restraining the potent activity of p53 and …
SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells
H Ozawa, RS Ranaweera, E Izumchenko… - Clinical Cancer …, 2017 - AACR
Purpose: We previously demonstrated an association between decreased SMAD4 expression
and cetuximab resistance in head and neck squamous cell carcinoma (HNSCC). The …
and cetuximab resistance in head and neck squamous cell carcinoma (HNSCC). The …
[HTML][HTML] A novel protein domain induces high affinity selenocysteine insertion sequence binding and elongation factor recruitment
J Donovan, K Caban, R Ranaweera… - Journal of biological …, 2008 - ASBMB
Selenocysteine (Sec) is incorporated at UGA codons in mRNAs possessing a Sec insertion
sequence (SECIS) element in their 3′-untranslated region. At least three additional factors …
sequence (SECIS) element in their 3′-untranslated region. At least three additional factors …
Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell …
…, M Considine, M Thakar, R Ranaweera… - Cancer biology & …, 2015 - Taylor & Francis
Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck
squamous cell carcinoma (HNSCC) and cetuximab, a monoclonal antibody targeting this …
squamous cell carcinoma (HNSCC) and cetuximab, a monoclonal antibody targeting this …
[HTML][HTML] Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance
…, LT Kagohara, S Li, M Thakar, R Ranaweera… - Genome medicine, 2018 - Springer
Background Targeted therapies specifically act by blocking the activity of proteins that are
encoded by genes critical for tumorigenesis. However, most cancers acquire resistance and …
encoded by genes critical for tumorigenesis. However, most cancers acquire resistance and …
[HTML][HTML] Model-informed experimental design recommendations for distinguishing intrinsic and acquired targeted therapeutic resistance in head and neck cancer
SD Cárdenas, CJ Reznik, R Ranaweera… - npj Systems Biology …, 2022 - nature.com
The promise of precision medicine has been limited by the pervasive resistance to many
targeted therapies for cancer. Inferring the timing (ie, pre-existing or acquired) and mechanism (…
targeted therapies for cancer. Inferring the timing (ie, pre-existing or acquired) and mechanism (…
[HTML][HTML] CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR …
…, LT Kagohara, G Krigsfeld, RS Ranaweera… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Patients with oncogene driven tumors are treated with targeted therapeutics including EGFR
inhibitors. Genomic data from The Cancer Genome Atlas (TCGA) demonstrates molecular …
inhibitors. Genomic data from The Cancer Genome Atlas (TCGA) demonstrates molecular …
[HTML][HTML] CancerInSilico: An R/Bioconductor package for combining mathematical and statistical modeling to simulate time course bulk and single cell gene expression …
…, M Considine, G Krigsfeld, R Ranaweera… - PLoS computational …, 2019 - journals.plos.org
Bioinformatics techniques to analyze time course bulk and single cell omics data are advancing.
The absence of a known ground truth of the dynamics of molecular changes challenges …
The absence of a known ground truth of the dynamics of molecular changes challenges …
Using Mathematical Modeling to Distinguish Intrinsic and Acquired Targeted Therapeutic Resistance in Head and Neck Cancer
SD Cardenas, CJ Reznik, R Ranaweera, F Song… - bioRxiv, 2022 - biorxiv.org
The promise of precision medicine has been limited by the pervasive therapeutic resistance
to many targeted therapies for cancer. Inferring the timing (ie, pre-existing or acquired) and …
to many targeted therapies for cancer. Inferring the timing (ie, pre-existing or acquired) and …
Immune profiling of head and neck squamous cell carcinoma (HNSCC) by a multiplex immunofluorescence (mIF) panel using multispectral microscopy.
…, T Van Veen, F Song, N Gimbrone, RS Ranaweera… - 2018 - ascopubs.org
6061 Background: Treatments based on immune checkpoint inhibition have shown great
promise in HNSCC. Comprehensive evaluation of lymphoid-inflamed tumor-immune …
promise in HNSCC. Comprehensive evaluation of lymphoid-inflamed tumor-immune …